Catalent seeks slice of gene therapy market with Paragon buy
(Reuters) – Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion…
by October Gallery
by October Gallery
(Reuters) – Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion…